Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. (ClinicalTrials.gov numbers, NCT00036439 and NCT00096655.)
No takes yet. Share an insight, caveat, or question.
Rutgeerts et al. (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: